Preterm Labor
Research on preterm labor and tocolytic therapy. Includes oxytocin antagonists, beta-agonists, calcium channel blockers, and other agents to delay preterm birth and allow corticosteroid administration.
Quick Answer
What it is
Research on preterm labor and tocolytic therapy. Includes oxytocin antagonists, beta-agonists, calcium channel blockers, and other agents to delay preterm birth and allow corticosteroid administration.
Key findings
- Grade A: Pregnancy Prolongation (48h-7 days) (Atosiban)
- Grade A: Maternal Tolerability vs Beta-Agonists (Atosiban)
- Grade A: Tocolytic Efficacy vs Beta-Agonists (Atosiban)
Safety
- vs Ritodrine: Adverse events 7.9% vs 70.8%, early termination 0% vs 20%.
- vs Terbutaline: Fewer clinically important adverse events.
- One trial noted increased fetal deaths at <24 weeks - use caution at early gestational ages.
ℹ️ Quick Facts
Quick Facts: Preterm Labor
- Supplements Studied:1
1 supps · 5 outcomes
Detailed Outcomes
A
Pregnancy Prolongation (48h-7 days)
Romero Phase 3 (n=501): Significantly more undelivered at 24h, 48h, and 7 days vs placebo (all P≤0.008) at ≥28 weeks. Allows time for corticosteroid administration. Less effective at <28 weeks gestational age.
moderate↑Improves
A
Maternal Tolerability vs Beta-Agonists
vs Ritodrine: Adverse events 7.9% vs 70.8%, early termination 0% vs 20%. vs Salbutamol: Better tolerated with comparable efficacy. vs Terbutaline: Fewer clinically important adverse events. No cardiovascular side effects seen with beta-agonists.
large↑Improves
A
Tocolytic Efficacy vs Beta-Agonists
vs Salbutamol: 48h efficacy 93.3% vs 95.0% (P=0.67). vs Terbutaline: 48h efficacy 86.1% vs 85.3% (P=0.78). Comparable tocolytic effectiveness with better safety profile. Some trials suggest slightly lower initial success rate.
none
A
Neonatal Outcomes
Cochrane 2014: No superiority vs placebo, beta-agonists, or CCBs for neonatal outcomes. Similar neonatal morbidity across comparators. One trial noted increased fetal deaths at <24 weeks - use caution at early gestational ages.
none
A
Maternal Side Effects
Most common: Nausea (mild). No tachycardia, hypotension, or hyperglycemia seen with beta-agonists. No pulmonary edema risk. Fewer treatment discontinuations. Generally well-tolerated by mother and fetus.
large↓Improves